First in vivo evaluation of the radiolabelled Hsp90 inhibitor [11C]Onalespib for cancer and brain PET imaging
This study presents the first preclinical evaluation of the radiolabelled Hsp90 inhibitor [¹¹C]Onalespib, demonstrating its high purity and specific binding to Hsp90 in vitro and in tumour tissues, while revealing limitations such as rapid metabolic degradation, variable tumour uptake, and negligible brain penetration that necessitate further optimization for clinical PET imaging.